Catalog No.
DHJ04001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen
Concentration
2.04 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q5ZPR3
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MG-A271, CAS: 1353485-38-7
Clone ID
Enoblituzumab
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis PMID: 27801901
A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. PMID: 28399405
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. PMID: 22615450
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). PMID: 30850021
A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155. PMID: 31308249
Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. PMID: 30027617
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. PMID: 31486697
MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. PMID: 27329595
TREM and TREM-like receptors in inflammation and disease. PMID: 19230638
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. PMID: 11224528
Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. PMID: 33976380
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. PMID: 31960110
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. PMID: 22001757
In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. PMID: 33925968
LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. PMID: 31731055
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. PMID: 28539467
B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. PMID: 30573782
Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. PMID: 18194267
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. PMID: 31578594
A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. PMID: 33057845
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. PMID: 29496042
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. PMID: 28024695
High expression of cluster of differentiation 276 indicates poor prognosis in glioma. PMID: 34366684
WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. PMID: 27721121
Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. PMID: 18690554
Regulation of Immunity by Butyrophilins. PMID: 26772212
Decreased m6A Modification of CD34/CD276(B7-H3) Leads to Immune Escape in Colon Cancer. PMID: 34307389
New checkpoints in cancer immunotherapy. PMID: 28258699
B7-H3: A promising therapeutic target for autoimmune diseases. PMID: 32113615
B7-H3 and its role in bone cancers. PMID: 31060912
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. PMID: 32742491
Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. PMID: 34601396
Isolation and characterization of CD276+/HLA-E+ human subendocardial mesenchymal stem cells from chronic heart failure patients: analysis of differentiative potential and immunomodulatory markers expression. PMID: 23013234
Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts. PMID: 21893365
Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma. PMID: 34565408
Expression status of PD-L1 and B7-H3 in mesothelioma. PMID: 33027549
Clinical relevance of B7H3 expression in retinoblastoma. PMID: 32576886
Magnetic Bead-Immobilized Mammalian Cells Are Effective Targets to Enrich Ligand-Displaying Yeast. PMID: 32283920
B7-H3-mediated tumor immunology: Friend or foe? PMID: 24013874
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting. PMID: 31267380
Costimulation, coinhibition and cancer. PMID: 17305475
B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role. PMID: 32992699
Frequent B7-H3 overexpression in craniopharyngioma. PMID: 31043272
Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. PMID: 33123243
The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas. PMID: 31959856
B7-H3 in tumors: friend or foe for tumor immunity? PMID: 29299639
Correction: PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma. PMID: 33931605
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. PMID: 28622628
Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display. PMID: 32166218
The role of B7 family molecules in hematologic malignancy. PMID: 23223433
Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma. PMID: 29480599
Identification of Hub Genes and Pathways in Preinfusion Chimeric Antigen Receptor (CAR) T-cell Products Associated With Cytokine Release Syndrome., PMID:40370902
ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration., PMID:39152118
B7-H3 Inhibitors in Oncology Clinical Trials: A Review., PMID:38327753
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial., PMID:37012549
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?, PMID:36555714
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial., PMID:35414591
Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy., PMID:34680929
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis., PMID:27801901
For research use only. Not for human or drug use.
